Personal Finance

Celgene's Fastest-Growing Drugs

A chart showing Otezla's quarterly sales growth in 2016

Celgene Corp (NASDAQ: CELG) is best known for Revlimid, a widely prescribed multiple myeloma therapy that saw sales jump 20% last year to $7 billion. That's impressive growth for a drug that's already a megablockbuster, but Revlimid isn't the company's fastest-growing medicine. Both Otezla and Pomalyst sales grew more quickly than Revlimid last year, and management thinks that's going to be the case again this year, too.

A chart showing Otezla's quarterly sales growth in 2016

Data source: Celgene. Chart by author.

What Otezla's peak sales potential may be is anyone's guess, but I think they could eclipse the $2 billion mark in a couple years. Why? Because Celgene's plans include launches in several major European markets and Japan soon, plus the potential to win regulatory nods in Eastern Europe, Asia, and Latin America, too.

Improving outcomes

Revlimid may be the most prescribed first- and second-line therapy in multiple myeloma, but Pomalyst has carved out an important niche for use in patients that have seen their disease return, or who have failed to respond to Revlimid.

Approved for use in the third-line setting, Pomalyst is increasingly being relied upon by a larger and longer-living patient population. The combination of a bigger addressable market, and patients remaining on Pomalyst for a longer period of time, led to Pomalyst's sales growing 33% year over year to $1.31 billion in 2016.

In Q4, Pomalyst's U.S. sales totaled $218.6 million and its international sales totaled $159.3 million, which works out to growth of between 28% to 29% worldwide. In 2017, ongoing trends toward more widespread use have Celgene forecasting Pomalyst revenue of $1.6 billion, up 22% from 2016. With fourth-quarter global revenue of $378 million, it appears Pomalyst is already well on its way to delivering on that guidance.

Looking ahead

Otezla's and Pomalyst's success have only strengthened Celgene's reputation as one of the industry's best developers of increasingly effective, top-selling medicine.

Opportunities to expand the use of Otezla and Pomalyst to more patients include trials evaluating Otezla in ulcerative colitis and Pomalyst in the second-line setting. If those trials -- and others -- prove these drugs are effective in more indications, it could lead to double-digit sales growth for years to come. Perhaps that's one big reason why Celgene thinks it can grow its total sales from $11.2 billion last year to more than $21 billion in 2020.

10 stocks we like better than Celgene

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celgene wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of January 4, 2017

Todd Campbell owns shares of Celgene.His clients may have positions in the companies mentioned.The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More